DREAM-ND (India)
Desidustat vs darbepoetin alfa
in non-dialysis CKD anaemia
n=36824 weeks2021
PublishedView summary Clinical evidenceEvidence across the
Evidence across the
CKD anaemia journey
The OXEMIA® (Desidustat) clinical evidence programme spans
transformed Phase III studies in non-dialysis and dialysis settings,
systematic reviews and guideline context, and real-world evidence.
Important outcomes remain uncertain and evidence certainty
for some endpoints has been rated low or very low.
1
Evidence map
Explore studies and resources by evidence type or setting.
DREAM-D (India)
Desidustat vs erythropoietin alfa
in dialysis-dependent CKD
n=34324 weeks2021
PublishedView summary China Phase III
Desidustat vs placebo in
non-dialysis CKD anaemia
n=40124 weeks2021
PublishedView summary Gulati et al. (2026)
Multicenter retrospective study in
INDO and CD cohorts
n=10486 months2025
PublishedView summary NDD-CKD systematic
review (Tyagi et al., 2025)
12 RCTs, 8611 participants
n=86112025
PublishedView summary 2
Pivotal programme overview
A comparison of the key clinical trials that evaluate desidustat.
DREAM-ND (India)
DREAM-D (India)
China Phase III
Population
Non-dialysis CKD (stages 3–5)
adults with anaemia
adults with anaemia
Dialysis-dependent CKD
adults with anaemia
adults with anaemia
Non-dialysis CKD adults
with anaemia
with anaemia
Study design / comparator
Randomised, open-label, active-controlled
vs darbepoetin alfa
vs darbepoetin alfa
Randomised, open-label, active-controlled
vs epoetin alfa
vs epoetin alfa
Randomised, double-blind, placebo-
controlled
controlled
Sample size
n=368
n=343
n=401
Duration
24 weeks
24 weeks
12 weeks
Primary endpoint
Non-inferiority for change in
haemoglobin (Hb)
haemoglobin (Hb)
Non-inferiority for change in
haemoglobin (Hb)
haemoglobin (Hb)
Hb correction, response and
target attainment
target attainment
Status
Published (2021)
Published (2021)
Published (2021)
3
Key evidence and resources
In addition to the pivotal trials, important context is provided by systematic reviews, guidelines and real-world studies.
NDD-CKD systematic
review (Tyagi et al., 2025)
12 RCTs (n=8611) evaluating HIF-PHIs
for anaemia in NDD-CKD.
Findings support HIF-PHIs as alternatives
to ESAs; evidence certainty generally
low or very low.
South Asia HIF-PHI
Guideline (2023)
Includes practice recommendations
for NDD and DD patients.
Desidustat might be offered as an
alternative to ESAs for appropriate
patients, when regulatory
requirements are met.
Gulati et al. (2026)
Real-world study
Multicenter retrospective study in CKD
patients including dialysis recipients.
Outcomes include Hb change in
Month 6 and dialysis vs routine practice.
Emerging research
(HCP access)
Observational transplant study,
PRCA case series and B19V series.
New-interventional data. Not for use
in treatment decisions.
4
Evidence gaps
Areas where more and better-quality evidence is needed.
cardiovascular
outcomes
MACE-plus data
quality-of-life
outcomes
progression-to-ESKD
outcomes
and cost-effectiveness
research
5
Continue exploring
Find what you need next.
See treatment in
routine practice
Explore real-world evidence
in CKD patients.
View emerging
medical research
Access selected HCP research
and investigator-initiated studies.
Review approved
dosing and safety
Access dosing details, safety
information and PI.